Drugs / EBNK-1822H2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07622940 | Mar 2026 → Mar 2027 expected | esophageal adenocarcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBNK-1822H2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07622940 ↗ |
| Modality | Cell therapy | “allogeneic cord blood-derived NK-cell product” NCT07622940 ↗ |
| Route | Intravenous | “one intravenous infusion on Day 0” NCT07622940 ↗ |